New Breakthrough Anticancer Drug Discovered
Researchers from the University of Florida College of Pharmacy have made a significant discovery in the field of cancer treatment. They have developed a new anticancer drug that offers improved safety and effectiveness compared to existing therapies.
This novel treatment, named DT2216, specifically targets leukemia, lymphoma, as well as breast and lung cancers. It focuses on inhibiting a protein called B-cell lymphoma-extra large (BCL-XL), which is responsible for promoting the growth of malignant cells and enhancing their resistance to therapy.
While an inhibitor for this protein already exists, it has the drawback of causing a drop in blood platelet levels, thereby increasing the risk of internal bleeding. Consequently, the US Food and Drug Administration did not approve the drug, prompting researchers to search for alternatives.
DT2216, the new drug developed by the researchers, demonstrates superior efficacy against various tumor cells dependent on the BCL-XL protein. Importantly, it also exhibits reduced toxicity towards blood platelets, addressing the previous safety concerns.
The development of this BCL-XL-targeting anticancer drug involves a technology that utilizes PROTACs, small molecules capable of suppressing and breaking down proteins that contribute to cancer growth.
Thus far, the researchers have demonstrated the drug's effectiveness in mathematical models as well as in mouse models. DT2216 successfully suppressed the growth of several tumor types, both when administered alone and in combination with other drugs.
The drug shows promise in treating T-cell acute lymphoblastic leukemia and drug-resistant breast and small-cell lung cancers, offering hope for patients suffering from these challenging diseases. Further research and clinical trials are necessary to validate its efficacy and safety in human subjects.
Further research needs to be conducted before they are able to file an Investigatory New Drug (IND) application, in order to conduct clinical trials on humans.
